Company intelligence / Profile preview

AirTrans

Cambridge, Massachusetts, United Statesairtransgroup.com ↗

Ownership: Private
Development stage: Other

Overview

AIRNA is advancing its lead candidate AIR-001 into a phase 1/2 trial for alpha‑1 antitrypsin deficiency. The company’s approach uses RNA editing to correct the PiZ mutation in the SERPINA1 gene. Additional preclinical programs target cardiometabolic and other diseases. No clinical efficacy data has been reported yet.

Therapeutic areas: Rare DiseasesMetabolic DisordersPulmonologyHematologyGastroenterologyCardiovascular
Modalities: RNA therapyGenetic medicine
Industry: Biotech

Partnerships

None publicly disclosed; open to future partnerships with larger companies

Beyond the preview

Go deeper on AirTrans.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AirTrans.

Explore the full profile